Stockscreener 앱 받기
3.925
3.09%
-0.125
전일 마감가:
$4.05
열려 있는:
$4.03
하루 거래량:
719.03K
Relative Volume:
0.73
시가총액:
$285.89M
수익:
$20.76M
순이익/손실:
$-132.49M
주가수익비율:
-1.3772
EPS:
-2.85
순현금흐름:
$-108.55M
1주 성능:
-16.84%
1개월 성능:
-37.20%
6개월 성능:
-31.86%
1년 성능:
+165.20%
1일 변동 폭
$3.89
$4.12
1주일 범위
$3.84
$4.9298
52주 변동 폭
$1.06
$11.88
C 4 Therapeutics Inc Stock (CCCC) Company Profile
명칭
C 4 Therapeutics Inc
전화
(617) 231-0700
주소
490 ARSENAL WAY, WATERTOWN
CCCC을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| CCCC | 3.925 | 285.89M | 20.76M | -132.49M | -108.55M | -2.85 |
| VRTX | 449.99 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 747.40 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 593.04 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 246.04 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 107.32 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
C 4 Therapeutics Inc Stock (CCCC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-02-24 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2023-02-24 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2022-11-04 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2022-10-11 | 개시 | Morgan Stanley | Underweight |
| 2022-04-28 | 개시 | Credit Suisse | Underperform |
| 2022-04-11 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-03-10 | 개시 | JP Morgan | Overweight |
| 2022-02-11 | 재개 | BMO Capital Markets | Outperform |
| 2022-02-10 | 개시 | Wells Fargo | Equal Weight |
| 2021-11-23 | 개시 | BofA Securities | Buy |
| 2021-10-14 | 개시 | SVB Leerink | Mkt Perform |
| 2021-09-30 | 개시 | Stifel | Hold |
| 2021-06-04 | 개시 | H.C. Wainwright | Buy |
| 2021-03-31 | 개시 | BMO Capital Markets | Outperform |
| 2020-10-28 | 개시 | UBS | Buy |
| 2020-10-27 | 개시 | BMO Capital Markets | Outperform |
| 2020-10-27 | 개시 | Jefferies | Buy |
모두보기
C 4 Therapeutics Inc 주식(CCCC)의 최신 뉴스
C4 Therapeutics appoints Steve Hoerter to board - Investing.com
C4 Therapeutics appoints Steve Hoerter to board By Investing.com - Investing.com UK
C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of Directors - The Bakersfield Californian
C4 Therapeutics Adds Oncology Veteran Steve Hoerter to Board, Brings Drug Launch Expertise | CCCC Stock News - StockTitan
C4 Therapeutics, Inc. Appoints Steve Hoerter as Board of Directors - Marketscreener.com
Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - The Manila Times
Stephens Initiates Coverage on C4 Therapeutics (NASDAQ:CCCC) - MarketBeat
Stephens & Co. Initiates Coverage of C4 Therapeutics (CCCC) with Equal-Weight Recommendation - MSN
C4 Therapeutics, Inc. (NASDAQ:CCCC) Sees Large Drop in Short Interest - MarketBeat
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Orbimed Advisors LLC Increases Stake in C4 Therapeutics Inc - GuruFocus.com
C4 Therapeutics, Inc.'s (NASDAQ:CCCC) 33% Share Price Plunge Could Signal Some Risk - Simply Wall St
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Crinetics Pharmaceuticals Announces November 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire
C4 Therapeutics: Holding Fast To A Generous Valuation Heading Into An Important ASH Readout - Seeking Alpha
CCCCC4 Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
C4 Therapeutics Announces First Patient Dosed in CFT8919 Clinical Trial - The Manila Times
C4 Therapeutics Launches Phase 1 Trial in China: $357M Cancer Drug Partnership Advances | CCCC Stock News - StockTitan
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
C4 Therapeutics to Present Data from the Ongoing Phase 1/2 Trial of Cemsidomide in Multiple Myeloma and Non-Hodgkin's Lymphoma At the American Society of Hematology Annual Meeting - Marketscreener.com
C4 Therapeutics to Present Data from the Ongoing Phase 1/2 Trial of Cemsidomide in Multiple Myeloma and Non-Hodgkin's Lymphoma at the American Society of Hematology (ASH) Annual Meeting - The Manila Times
C4 Therapeutics' Cemsidomide Trial Data Selected for Key ASH Presentations in NHL, Myeloma | CCCC Stock News - StockTitan
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Will C4 Therapeutics' Upcoming Multiple Myeloma And NHL Trial Results Drive Stock Recovery? - RTTNews
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
ORIC® Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Marketscreener.com
C4 Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
C4 Therapeutics Advances in Protein Degradation Therapy - TipRanks
C4 Therapeutics, Inc. (CCCC) Reports Q3 Loss, Tops Revenue Estimates - MSN
C4 Therapeutics (CCCC) Q3 2024 Earnings: Revenue Surges to $15.4M, GAAP EPS Loss Narrows to $0.35 - GuruFocus.com
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
C4 Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights - The Manila Times
C4 Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
C4 Therapeutics, Inc. (NASDAQ:CCCC) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
We're Hopeful That C4 Therapeutics (NASDAQ:CCCC) Will Use Its Cash Wisely - Yahoo Finance
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
C4 Therapeutics, Inc. (NASDAQ:CCCC) Short Interest Update - MarketBeat
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Citizentribune
C4 Therapeutics appoints Paige Mahaney as new CSO - Investing.com India
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
C 4 Therapeutics Inc (CCCC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.80%
0.42%
자본화:
|
볼륨(24시간):